Diabetic Macular Edema Market is Projected to Boost at a Moderate Growth Rate During the Forecast Period (2022-2032) - DelveInsight | Key Companies - Ocuphire Pharma, AsclepiX, Celltrion, Curacle, Eluminex, Exonate, GlaxoSmithKline, Mylan, Ocugen, Unity B

As per DelveInsight, the Diabetic Macular Edema Market size was USD 2.9 billion in 2021, which is expected to grow by 2032. The Diabetic Macular Edema Market is anticipated to grow in the coming years owing to the increase in the diabetic population, changes in lifestyle, growing awareness about Diabetic Macular Edema, the rise in healthcare expenditure, and the launch of new therapies in the market.

DelveInsight's "Diabetic Macular Edema Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Diabetic Macular Edema Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Diabetic Macular Edema market report covers emerging drugs, treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Diabetic Macular Edema: An Overview
Diabetic Macular Edema (DME) is triggered by diabetic retinopathy (DR), a well-known complication of diabetes. DR is the most prevalent diabetic eye disease and the leading cause of irreversible blindness in people in their working years in developed and other developing countries. Common signs and symptoms include dark spots like a smudge on glasses or gaps that may appear in the vision, blurred vision, double vision, colors can fade, or the affected person may find bright light or glare difficult.

All people with Type 1 or Type 2 diabetes are at risk for DR and DME. The risk of developing DR or Diabetic Macular Edema increases significantly the longer a person has diabetes. The American Academy of Ophthalmology (AAO) estimates that nearly 80% of patients with Type 1 diabetes will have developed DR after living with diabetes for 15 years. There are 50% chance that patients with Type 2 diabetes will develop DR after living with diabetes for around 20 years.

Diabetic Macular Edema Market Key Facts
• In the 7MM, the total treated cases of Diabetic Macular Edema in first-line were nearly 440,000 cases in 2021. The analysis shows these cases are expected to reach 520,000 by 2032. Approximately 110,000 patients progressed from first-line to second-line and above, and are expected to increase by 2032.
• In 2021, the total prevalent cases of Diabetic Macular Edema were the highest in the US, with more than 1 million cases, and lowest in France, with 60,000 cases.
• Among EU4 and the UK, Germany had the highest number of prevalent cases of Diabetic Macular Edema (approximately 220,000 cases) in 2021.
• Japan accounted for approximately 194,000 cases in 2019, which is nearly 11% of the total Diabetic Macular Edema prevalent cases in the 7MM. These cases are anticipated to reach to 196,000 cases by the year 2032.
• Germany accounted for ~100,000 diagnosed prevalent cases in 2021, which is expected to increase to approximately 103,500 cases by the year 2032.

Discover How Diabetic Macular Edema Market will Grow by 2032:
https://www.delveinsight.com/report-store/diabetic-macular-edema-dme-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Diabetic Macular Edema Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Diabetic Macular Edema market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the Diabetic Macular Edema market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Diabetic Macular Edema Epidemiology
The epidemiology section covers detailed insights into the historical and current Diabetic Macular Edema patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Diabetic Macular Edema Epidemiology Segmented as -
• Total Prevalent Cases of DME in the 7MM (2019-2032)
• Gender-specific Diagnosed Cases of DME in the 7MM (2019-2032)
• Total Diagnosed Cases of DME in the 7MM (2019-2032)
• Age-Specific Diagnosed Cases of DME in the 7MM (2019-2032)
• Treated cases of DME in the 7MM (2019-2032)
• Subgroup-specific Diagnosed Cases of DME in the 7MM (2019-2032)

Get Key Insights Into the Evolving Diabetic Macular Edema Epidemiology Trends:
https://www.delveinsight.com/report-store/diabetic-macular-edema-dme-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Diabetic Macular Edema Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Diabetic Macular Edema market or expected to be launched during the study period. The analysis covers Diabetic Macular Edema market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Diabetic Macular Edema Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities:
https://www.delveinsight.com/sample-request/diabetic-macular-edema-dme-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Diabetic Macular Edema Therapeutics Assessment
Several major pharma and biotech companies are developing therapies for Diabetic macular edema. Currently, Mylan Pharmaceuticals is leading the therapeutics market with its Diabetic macular edema drug candidates in the most advanced stage of clinical development.

The Leading Players in the Diabetic Macular Edema Therapeutics Market Include:
• Adverum Biotechnologies
• Allergan (AbbVie)
• Allergo Ophthalmics
• Allgenesis Biotherapeutics
• Ascentage Pharma
• AsclepiX Therapeutics
• Bausch Health
• Celltrion
• Clearside Biomedical
• Exonate
• Graybug Vision
• KalVista Pharmaceuticals
• Kodiak Sciences
• MingSight Pharmaceuticals
• Molecular Partners
• Mylan Pharmaceuticals
• Novartis
• Ocuphire Pharma
• Opthea
• Oxurion
• Rezolute
• Roche
• YD Life Science
And Many Othres

Diabetic Macular Edema Emerging and Marketed Drugs Covered in the Report Include:
• APX3330: Ocuphire Pharma
• AXT107: AsclepiX Therapeutics
• CT-P42: Celltrion
• CU06-1004: Curacle
• EB-102: Eluminex BioSciences
• EXN407: Exonate Limited
• GSK-2798745: GlaxoSmithKline
• KSI-301: Kodiak Sciences
• MYL-1701P: Mylan Pharmaceuticals
• OCU200: Ocugen
• UBX1325: Unity Biotechnology
And Many More

Learn More About the Emerging Therapies & Key Companies in the Diabetic Macular Edema Therapeutics Market:
https://www.delveinsight.com/sample-request/diabetic-macular-edema-dme-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Diabetic Macular Edema Competitive Intelligence Analysis
4. Diabetic Macular Edema Market Overview at a Glance
5. Diabetic Macular Edema Background and Overview
6. Diabetic Macular Edema Patient Journey
7. Diabetic Macular Edema Epidemiology and Patient Population
8. Diabetic Macular Edema Treatment Algorithm, Current Treatment, and Medical Practices
9. Diabetic Macular Edema Unmet Needs
10. Key Endpoints of Diabetic Macular Edema Treatment
11. Diabetic Macular Edema Marketed Products
12. Diabetic Macular Edema Emerging Therapies
13. Diabetic Macular Edema Seven Major Market Analysis
14. Attribute Analysis
15. Diabetic Macular Edema Market Outlook (7 major markets)
16. Diabetic Macular Edema Access and Reimbursement Overview
17. KOL Views on the Diabetic Macular Edema Market.
18. Diabetic Macular Edema Market Drivers
19. Diabetic Macular Edema Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings:
https://www.delveinsight.com/sample-request/diabetic-macular-edema-dme-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Other Trending Reports by DelveInsight-)
- Chronic Refractory Gout Market
https://www.delveinsight.com/report-store/chronic-refractory-gout-market

- Complicated Intra-Abdominal Infections Market
https://www.delveinsight.com/report-store/complicated-intra-abdominal-infections-market

- Duchenne Muscular Dystrophy Market
https://www.delveinsight.com/report-store/duchenne-muscular-dystrophy-market

- Gonorrhea Market
https://www.delveinsight.com/report-store/gonorrhea-market

- Hypercalcemia Market
https://www.delveinsight.com/report-store/hypercalcemia-market

- Lenegre's disease Market
https://www.delveinsight.com/report-store/lenegres-disease-market

- Mitochondrial Myopathies Market
https://www.delveinsight.com/report-store/mitochondrial-myopathies-market

- Mucinous cystic neoplasms (MCNs) Market
https://www.delveinsight.com/report-store/mucinous-cystic-neoplasms-mcns-market

- Obsessive-Compulsive Disorder Market
https://www.delveinsight.com/report-store/obsessive-compulsive-disorder-market

- Osteochondromas Market
https://www.delveinsight.com/report-store/osteochondromas-market

- Preeclampsia Market
https://www.delveinsight.com/report-store/preeclampsia-market

- Uterine Serous Carcinoma Market
https://www.delveinsight.com/report-store/uterine-serous-carcinoma-market

- Vasomotor symptoms (Hot flashes/Night sweats) Market
https://www.delveinsight.com/report-store/vasomotor-symptoms-market

- Venous Leg Ulcer Market
https://www.delveinsight.com/report-store/venous-leg-ulcer-market

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.